China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions, announced that it has received clinical approvals from the National Medical Products Administration (NMPA) for its MWN109, a triple agonist of GIP, GLP-1, and GCG. The drug is indicated for the treatment of type 2 diabetes and overweight/obesity.
Mechanism of Action
MWN109 works by stimulating pancreatic beta cells to secrete insulin, effectively controlling blood sugar levels. It also delays gastric emptying and inhibits gastric acid secretion. Additionally, it increases satiety, reduces energy intake, and promotes fat breakdown. These actions collectively increase energy expenditure and basal metabolism, leading to effective weight reduction.-Fineline Info & Tech
